1
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Glycart Biotechnology, Sterne Kessler Goldstein & Fox p l l c, August 5, 2003: US06602684 (224 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


2
Pablo Umaña, Joël Jean Mairet, M Sean Bailey legal representative: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. GlycArt Biotechnology, Sterne Kessler Goldstein & Fox PLLC, April 14, 2009: US07517670 (35 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


3
Pablo Umana, Joel Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Glycart Biotechnology, Sterne Kessler Goldstein & Fox P L L C, March 15, 2011: US07906329 (27 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


4
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, Timothy J Shea Jr, January 7, 2014: US08623644 (14 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


5
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, Timothy J Shea Jr, January 14, 2014: US08629248 (13 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


6
Umana Pablo Dr, Joel Jean Mairet, Bailey James E Prof Dr: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Umana Pablo, Jean Mairet Joel, Bailey James E, January 31, 2001: EP1071700-A1 (7 worldwide citation)

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein t ...


7
Umana Pablo, Jean Mairet Joel, Bailey James E: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Umana Pablo, Jean Mairet Joel, Bailey James E, ABRAMS Samuel B, October 28, 1999: WO/1999/054342 (5 worldwide citation)

The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein t ...


8
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlyeArt, Sterne Kessler Goldstein & Fox P L L C, Timothy J Shea Jr, September 22, 2015: US09139654 (2 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


9
Pablo Umaña, Joël Jean Mairet, James E Bailey: Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. Roche GlycArt, Sterne Kessler Goldstein & Fox P L L C, June 30, 2015: US09068005 (2 worldwide citation)

The present invention relates to the field glycosylation engineering of proteins. More particular, the present invention is directed to the glycosylation engineering of proteins to provide proteins with improved therapeutic properties, e.g., antibodies, antibody fragments, or a fusion protein that i ...


10
UMANA PABLO, JEAN MAIRET JOEL, BAILEY JAMES E: [fr] Ingénierie de glycosylation pour anticorps afin daméliorer la cytotoxicité cellulaire en fonction de lanticorps, [de] Glykosylationstechnik für Antikörper zur Verbesserung der antikörperabhängigen Zellenzytotoxizität, [en] Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity. GLYCART BIOTECHNOLOGY, April 28, 2010: EP2180007-A2

[en] The present invention provides a glycosylation engineered mammalian host cell that expresses a recombinant antibody comprising an IgG Fc region containing N-linked oligosaccharides, wherein said host cell has been genetically modified to regulate the increased expression of at least one enzyme ...